145 results
Page 2 of 8
8-K
EX-99.1
gjcf jia1i
9 Sep 22
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
7:14am
424B5
y11lw
28 Apr 22
Prospectus supplement for primary offering
8:09am
8-K
EX-99.1
7o8othja0b9t dk6
12 Nov 21
Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS
6:30am
8-K
EX-99.1
0dvq9xxe1lrjv
4 Nov 21
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:40am
8-K
EX-99.1
rgptgc
13 Sep 21
Other Events
7:08am
8-K
EX-99.1
xw3tbom1zyap46
19 May 21
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
5:08pm
8-K
EX-99.1
xaqo7abe38rg 1w3ft
19 Nov 20
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
9:09am